In contrast, genes belonging to the second group and their encoded proteins might play more substantial role in the progression of pathological changes from the pre‐symptomatic to symptomatic stage and therefore constitute more credible molecular targets for therapeutic intervention, at least in ALS‐FUS cases. The gene discussed is FUS; the disease is amyotrophic lateral sclerosis.